Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
Lost Money on AstraZeneca PLC(AZN)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
10:15am, Wednesday, 29'th Jan 2025
NEW YORK, NY / ACCESS Newswire / January 29, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities law
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca
09:49am, Wednesday, 29'th Jan 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In AstraZenecaTo Contact Him Directly To Discuss Their Options
NEW YORK, NY / ACCESS Newswire / January 29, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities law
AZN Shareholders Have Opportunity to Lead AstraZeneca PLC Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
07:00am, Wednesday, 29'th Jan 2025
NEW YORK CITY, NY / ACCESS Newswire / January 29, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Ast
Shareholders of AstraZeneca PLC Should Contact Levi & Korsinsky Before February 21, 2025 to Discuss Your Rights - AZN
02:45pm, Tuesday, 28'th Jan 2025
NEW YORK, NY / ACCESS Newswire / January 28, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities law
Investors in AstraZeneca PLC Should Contact Levi & Korsinsky Before February 21, 2025 to Discuss Your Rights - AZN
01:00pm, Tuesday, 28'th Jan 2025
NEW YORK CITY, NY / ACCESS Newswire / January 28, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securitie
FDA Expands Label of AZN's Enhertu for New Breast Cancer Indication
12:15pm, Tuesday, 28'th Jan 2025
The FDA approves AstraZeneca's sBLA for Enhertu to treat HER2-low or HER2-ultralow metastatic breast cancer in the United States.
NEW YORK CITY, NY / ACCESS Newswire / January 28, 2025 / WHY: New York, N.Y., January 28, 2025.
NEW YORK , Jan. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN). Such investors are advised
AstraZeneca PLC Is Being Sued For Securities Law Violations And Impacted Shareholders Are Urged To Contact The Schall Law Firm
11:00am, Tuesday, 28'th Jan 2025
LOS ANGELES, CA / ACCESS Newswire / January 28, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AstraZeneca PLC ("AstraZe
AZN Investors Have Opportunity to Lead AstraZeneca PLC Securities Fraud Lawsuit with the Schall Law Firm
10:23am, Tuesday, 28'th Jan 2025
LOS ANGELES , Jan. 28, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AstraZeneca PLC ("AstraZeneca" o
AZN Investors Have Opportunity to Lead AstraZeneca PLC Class Action Lawsuit - Contact Bronstein, Gewirtz and Grossman, LLC Today!
07:00am, Tuesday, 28'th Jan 2025
NEW YORK CITY, NY / ACCESS Newswire / January 28, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Ast
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 21, 2025 in AstraZeneca Lawsuit - AZN
06:45am, Tuesday, 28'th Jan 2025
NEW YORK , Jan. 28, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit. CLASS DEFINITI
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Daiichi Sankyo's ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or met
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU Approved in the U.S. as First HER2 Directed Therapy for HER2 Low or HER2 Ultralow mBC Following Disease Progression After Endocrine Therapy.
